/
/
Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma
Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma image
Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma
Posted Feb 11, 2017

Which combination therapy is best for newly diagnosed myeloma patients? This randomized phase III study compares bortezomib, lenalidomide and dexamethasone (RVd) with carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed patients. Both options are considered "standard of care" treatments for newly diagnosed multiple myeloma. This study is open at 21 different locations in Wisconsin. Click here to learn more: Newly Diagnosed Myeloma Clinical Trial  

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811